Show simple item record

dc.contributor.authorSeufert, R
dc.contributor.authorSedlacek, L
dc.contributor.authorKahl, B
dc.contributor.authorHogardt, M
dc.contributor.authorHamprecht, A
dc.contributor.authorHaase, G
dc.contributor.authorGunzer, F
dc.contributor.authorHaas, A
dc.contributor.authorGrauling-Halama, S
dc.contributor.authorMacKenzie, C R
dc.contributor.authorEssig, A
dc.contributor.authorStehling, F
dc.contributor.authorSutharsan, S
dc.contributor.authorDittmer, S
dc.contributor.authorKillengray, D
dc.contributor.authorSchmidt, D
dc.contributor.authorEskandarian, N
dc.contributor.authorSteinmann, E
dc.contributor.authorBuer, J
dc.contributor.authorHagen, F
dc.contributor.authorMeis, J F
dc.contributor.authorRath, P-M
dc.contributor.authorSteinmann, J
dc.date.accessioned2018-10-11T07:11:20Z
dc.date.available2018-10-11T07:11:20Z
dc.date.issued2018-08-01
dc.identifier.issn1460-2091
dc.identifier.pmid29684150
dc.identifier.doi10.1093/jac/dky147
dc.identifier.urihttp://hdl.handle.net/10033/621513
dc.description.abstractAspergillus fumigatus is the most prevalent filamentous fungus in the respiratory tract of patients with cystic fibrosis (CF). The aim of this prospective multicentre study was to investigate the prevalence of azole-resistant A. fumigatus (ARAF) in respiratory secretions from CF patients across Germany and to characterize ARAF isolates by phenotypic and molecular methods. Twelve tertiary care centres from Germany participated in the study. In total, 2888 A. fumigatus isolates from 961 CF patients were screened for ARAF by using azole-containing agar plates. Antifungal susceptibility testing of isolates was performed by broth microdilution according to EUCAST guidelines. Analysis of mutations mediating resistance was performed using PCR and sequencing of the cyp51A gene. Furthermore, genotyping by microsatellite PCR was performed. Of a total of 2888 A. fumigatus isolates, 101 isolates from 51 CF patients were found to be azole resistant (prevalence per patient 5.3%). The Essen centre had the highest prevalence (9.1%) followed by Munich (7.8%), Münster (6.0%) and Hannover (5.2%). Most ARAF isolates (n = 89) carried the TR34/L98H mutation followed by eight G54E/R, one TR46/Y121F/T289A and one F219S mutation. In two isolates no mutation was found. Genotyping results showed no major clustering. Forty-five percent of CF patients with ARAF had previously received azole therapy. This is the first multicentre study analysing the prevalence of ARAF isolates in German CF patients. Because of a resistance rate of up to 9%, susceptibility testing of A. fumigatus isolates from CF patients receiving antifungal treatment should be part of standard diagnostic work-up.en_US
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/us/*
dc.titlePrevalence and characterization of azole-resistant Aspergillus fumigatus in patients with cystic fibrosis: a prospective multicentre study in Germany.en_US
dc.typeArticleen_US
dc.contributor.departmentTWINCORE, Zentrum für experimentelle und klinischeInfektionsforschung GmbH, Feodor-Lynen-Str. 7, 30625 Hannover, Germany.en_US
dc.source.journaltitleThe Journal of antimicrobial chemotherapy


Files in this item

Thumbnail
Name:
Seufert et al.pdf
Size:
869.8Kb
Format:
PDF
Description:
original manuscript

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 3.0 United States